Effects of torcetrapib in patients at high risk for coronary events
Effects of torcetrapib in patients at high risk for coronary events
复制标题
DOI：
10.1056/nejmoa0706628
复制
发表时间：
2007-11-22
影响因子：
158.5
通讯作者：
Brewer, Bryan
中科院分区：
文献类型：
--
作者：
Barter, Philip J.;Caulfield, Mark;Brewer, Bryan
背景胆固醇酯转移蛋白（CETP）的抑制已被证明对血浆脂蛋白水平有实质性影响。我们研究了一种有效的CETP抑制剂torcetrapib是否可以减少主要的心血管事件。该试验提前终止，因为死亡和心脏事件的患者接受torcetrapib.Methods的风险增加，我们进行了一项随机，双盲研究，涉及15,067例心血管高风险患者。患者接受torcetrapib+阿托伐他汀或阿托伐他汀单药治疗。主要结果是首次主要心血管事件发生的时间，首次主要心血管事件定义为冠心病死亡、非致命性心肌梗死、中风或因不稳定型心绞痛住院治疗。结果在接受torcetrapib治疗的患者中，12个月时高密度脂蛋白胆固醇增加72.1%，低密度脂蛋白胆固醇减少24.9%，与基线相比（P
Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.Methods We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.Results At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P